[go: up one dir, main page]

WO2008056375A3 - Formulations pharmaceutiques comprenant du valsartan - Google Patents

Formulations pharmaceutiques comprenant du valsartan Download PDF

Info

Publication number
WO2008056375A3
WO2008056375A3 PCT/IN2007/000516 IN2007000516W WO2008056375A3 WO 2008056375 A3 WO2008056375 A3 WO 2008056375A3 IN 2007000516 W IN2007000516 W IN 2007000516W WO 2008056375 A3 WO2008056375 A3 WO 2008056375A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
angiotensin
antagonist
prepared
valsartan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2007/000516
Other languages
English (en)
Other versions
WO2008056375A2 (fr
Inventor
Anirudha Kute
Nikhil Prabhakar Malewar
Makarand Krishnakumar Avachat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of WO2008056375A2 publication Critical patent/WO2008056375A2/fr
Publication of WO2008056375A3 publication Critical patent/WO2008056375A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant un antagoniste de l'angiotensine II, ladite composition pharmaceutique étant préparée par granulation en voie humide ; une composition pharmaceutique comprenant un antagoniste de l'angiotensine II et un ou plusieurs diurétiques, ladite composition pharmaceutique étant préparée par granulation en voie humide ; une composition pharmaceutique préparée par granulation en voie humide comprenant un agent actif comprenant une quantité efficace d'un antagoniste de l'angiotensine II et des additifs acceptables du point de vue pharmaceutique, l'agent actif étant présent en quantité inférieure à 35 % en poids sur la base du poids total de la composition pharmaceutique.
PCT/IN2007/000516 2006-11-09 2007-11-02 Formulations pharmaceutiques comprenant du valsartan Ceased WO2008056375A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1200/KOL/2006 2006-11-09
IN1200KO2006 2006-11-09

Publications (2)

Publication Number Publication Date
WO2008056375A2 WO2008056375A2 (fr) 2008-05-15
WO2008056375A3 true WO2008056375A3 (fr) 2008-07-10

Family

ID=39322620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000516 Ceased WO2008056375A2 (fr) 2006-11-09 2007-11-02 Formulations pharmaceutiques comprenant du valsartan

Country Status (1)

Country Link
WO (1) WO2008056375A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110027358A1 (en) * 2007-03-29 2011-02-03 Rajesh Kshirsagar Valsartan tablet formulations
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
KR101509489B1 (ko) * 2008-11-10 2015-04-08 (주)아모레퍼시픽 발사르탄을 함유하는 고형 경구제형의 제조 방법
EP2536396B1 (fr) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
CN102247376B (zh) * 2011-08-15 2012-11-28 华润赛科药业有限责任公司 复方缬沙坦氢氯噻嗪固体制剂及其制备方法
KR101446603B1 (ko) * 2011-11-22 2014-10-07 주식회사 인트로팜텍 텔미사르탄을 포함하는 단층정 복합 제제
WO2013098576A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique de valsartan à libération immédiate
WO2013098578A1 (fr) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2005082329A2 (fr) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Procede de preparation de formes posologiques solides de valsartan et d'hydrochlorthiazide
WO2005089720A1 (fr) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Comprimes a base de valsartan et procede de preparation associe
EP1674080A1 (fr) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant du valsartan

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2005082329A2 (fr) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Procede de preparation de formes posologiques solides de valsartan et d'hydrochlorthiazide
WO2005089720A1 (fr) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Comprimes a base de valsartan et procede de preparation associe
EP1674080A1 (fr) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant du valsartan

Also Published As

Publication number Publication date
WO2008056375A2 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008056375A3 (fr) Formulations pharmaceutiques comprenant du valsartan
WO2005089729A3 (fr) Formulations galeniques de composes organiques
WO2008140507A3 (fr) Formulations de nanoparticules et de polymères pour les analogues, les antagonistes et les formulations de l'hormone thyroïde et leurs utilisations
WO2007048219A3 (fr) Composition medicamenteuse a liberation prolongee
WO2008051291A3 (fr) Nanoparticule et formes polymères d'analogues et d'antagonistes de l'hormone thyroïdienne et leurs formulations
WO2008023016A3 (fr) Formulations galéniques de composés organiques
WO2006084164A3 (fr) Systeme d'administration a retention gastrique et a liberation lente
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2007086001A3 (fr) Nouveaux dérivés de pyridine
WO2007098128A3 (fr) Formules liquides de phényléphrine
WO2010038091A9 (fr) Composition pharmaceutique a combinaison stable
WO2004022002A3 (fr) Composition analgesique combinee a liberation immediate et prolongee
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2007048027A3 (fr) Combinaison de composes organiques
EP1584335A3 (fr) Combinaison de substances actives comprenant un composé carbinol et un opioïde
WO2006008173A3 (fr) Formulations pharmaceutiques
WO2008065144A3 (fr) Préparations galéniques de composés organiques
WO2007084212A3 (fr) Composition biologiquement active contenant de l'éthylcellulose
WO2007121471A3 (fr) Agents d'administration des éthers dialkyliques
WO2009110010A3 (fr) Forme posologique orale stable
WO2005107702A3 (fr) Compositions pharmaceutiques vaginales mucoadhesives a liberation prolongee
WO2007009691A3 (fr) Combinaison de substances active s
WO2007116297A3 (fr) Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies
WO2007060384A3 (fr) Poudres respirables
WO2008015202A3 (fr) Compositions pharmaceutiques anticonvulsives

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07849683

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07849683

Country of ref document: EP

Kind code of ref document: A2